Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Non-Current Liabilities: 2009-2025

Historic Other Non-Current Liabilities for Northwest Biotherapeutics (NWBO) over the last 13 years, with Sep 2025 value amounting to $60.8 million.

  • Northwest Biotherapeutics' Other Non-Current Liabilities rose 87.02% to $60.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.8 million, marking a year-over-year increase of 87.02%. This contributed to the annual value of $46.2 million for FY2024, which is 97.40% up from last year.
  • Northwest Biotherapeutics' Other Non-Current Liabilities amounted to $60.8 million in Q3 2025, which was up 26.02% from $48.3 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Other Non-Current Liabilities ranged from a high of $350.4 million in Q1 2021 and a low of $10.0 million during Q2 2023.
  • In the last 3 years, Northwest Biotherapeutics' Other Non-Current Liabilities had a median value of $26.6 million in 2024 and averaged $31.9 million.
  • Per our database at Business Quant, Northwest Biotherapeutics' Other Non-Current Liabilities soared by 392.69% in 2021 and then tumbled by 90.29% in 2023.
  • Northwest Biotherapeutics' Other Non-Current Liabilities (Quarterly) stood at $116.0 million in 2021, then dropped by 21.80% to $90.7 million in 2022, then plummeted by 74.22% to $23.4 million in 2023, then spiked by 97.40% to $46.2 million in 2024, then spiked by 87.02% to $60.8 million in 2025.
  • Its Other Non-Current Liabilities was $60.8 million in Q3 2025, compared to $48.3 million in Q2 2025 and $47.2 million in Q1 2025.